AstraZeneca PLC (NASDAQ: AZN) announced on Monday that its Phase III LATIFY clinical trial evaluating ceralasertib in ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

U.S. health officials have raised concerns over AstraZeneca’s COVID-19 vaccine trial, accusing the pharmaceutical giant of using outdated and potentially misleading efficacy data. “The DSMB expressed ...

JOHANNESBURG, Dec 9 (Reuters) - Efficacy results may not be ready for months from a trial of AstraZeneca and Oxford University's coronavirus vaccine in South Africa, the principal investigator of the ...

AstraZeneca and Oxford University announced on Monday that they had developed a new Covid-19 vaccine with an efficacy rate of 70 to 90 percent. Trials indicated the vaccine could prevent 70 percent of ...

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety findings” linked to the British drugmaker’s bleeding reversal agent. At ...

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc’s (NASDAQ:AZN) supplemental biologics license application for Andexxa (coagulation factor Xa ...

SAN FRANCISCO -- Another COVID-19 vaccine -- AstraZeneca -- is poised to arrive in the U.S., bringing a fourth option for Americans. Each vaccine is administered slightly differently, some can result ...

FRANKFURT, Jan 25 (Reuters) - AstraZeneca (AZN.L), opens new tab on Monday described German media reports saying its COVID-19 vaccine was shown to have a very low efficacy in the elderly as ...